A phase I open label dose escalation study for the safety and tolerability of AZD2171 [cediranib] in solid tumors in Japan.
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2016
At a glance
- Drugs Cediranib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 17 Jun 2009 Actual patient number (40) added as reported by ClinicalTrials.gov.
- 17 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2007 New trial record.